Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2008. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (Dr. Slaoui) and a connected person, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of executive compensation transactions rather than a financial results report.
Material Changes
On February 19, 2008, a connected person of Dr. Slaoui received the following awards:
- GlaxoSmithKline Performance Share Plan: 1,570 ADSs
- GlaxoSmithKline Share Option Plan: 3,570 ADSs
- GlaxoSmithKline Share Value Plan: 890 ADSs
The share options were granted at a subscription price of $44.75 per ADS.
Guidance, Outlook, and Conditions
The filing outlines specific vesting conditions for the awards:
- Performance Share Plan: Vesting is subject to GlaxoSmithKline's Total Shareholder Return (TSR) performance and the growth in earnings per share over the performance period from January 1, 2008, to December 31, 2010.
- Share Value Plan: Vesting is subject to continued employment.
The Company and the connected person were advised of these transactions on February 20, 2008, in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the subscription price of $44.75 per ADS against the market price on February 19, 2008.
- Confirm the specific TSR and EPS growth targets defined for the 2008-2010 performance period.
- Review the employment status of the connected person to assess the risk of forfeiture for the Share Value Plan.
- Check subsequent filings for the actual vesting outcomes of these awards.